Osteoarthritis Pain Pipeline Review, H2 2020: Therapeutics Development & Assessment, Drug Profiles, Dormant Projects, Discontinued Products, Product Development Milestones – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Osteoarthritis Pain – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Osteoarthritis Pain – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Osteoarthritis Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 7, 22, 8, 1, 12, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Osteoarthritis Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Osteoarthritis Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. (Read more…)
• The pipeline guide reviews key companies involved in Osteoarthritis Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Osteoarthritis Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis Pain (Central Nervous System)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Osteoarthritis Pain (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Osteoarthritis Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Osteoarthritis Pain – Overview
• Osteoarthritis Pain – Therapeutics Development
• Osteoarthritis Pain – Therapeutics Assessment
• Osteoarthritis Pain – Companies Involved in Therapeutics Development
• Osteoarthritis Pain – Drug Profiles
• Osteoarthritis Pain – Dormant Projects
• Osteoarthritis Pain – Discontinued Products
• Osteoarthritis Pain – Product Development Milestones
• Appendix

Companies Mentioned

• Achelios Therapeutics Inc
• AKL Research and Development Ltd
• AlzeCure Pharma AB
• Ampio Pharmaceuticals Inc
• Andros Pharmaceuticals Co Ltd
• AntalGenics SL
• Antibe Therapeutics Inc
• Apimeds Inc
• Aquilus Pharmaceuticals Inc
• AstraZeneca Plc
• Axsome Therapeutics Inc
• Calchan Ltd
• Cara Therapeutics Inc
• Centrexion Therapeutics Corp
• Chromocell Corp
• Concentric Analgesics Inc
• Eli Lilly and Co
• Elite Pharmaceuticals Inc
• Eupraxia Pharmaceuticals Inc
• EyePoint Pharmaceuticals Inc
• Futura Medical Plc
• GlaxoSmithKline Plc
• Grunenthal GmbH
• Hisamitsu Pharmaceutical Co Inc
• iN Therapeutics
• Iroko Pharmaceuticals LLC
• Levicept Ltd
• Mestex AG
• Nuvo Pharmaceuticals Inc
• Olatec Therapeutics LLC
• OliPass Corporation
• Ono Pharmaceutical Co Ltd
• Peptide Logic LLC
• Pfizer Inc
• Pharmnovo AB
• ProteoThera Inc
• RaQualia Pharma Inc
• Regeneron Pharmaceuticals Inc
• Rottapharm Biotech Srl
• Sansho Co Ltd
• Shionogi & Co Ltd
• Shulov Innovative Science Ltd
• Sorrento Therapeutics Inc
• Symic Bio Inc
• Taiwan Liposome Co Ltd
• Techfields Pharma Co Ltd
• Vertex Pharmaceuticals Inc
• Xalud Therapeutics Inc
• Xenexus Pharmaceuticals Pty Ltd
• Zhejiang Yatai Pharmaceutical Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/4kmlrv

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900